FutureGen Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$42.8M
- Investors
-
6
FutureGen General Information
Description
Developer of biological R&D platform intended to discover antibody new drugs. The company develops antibody drugs to better treat cancer and tumor diseases, enabling patients to get better treatments.
Contact Information
Website
www.futuregen.com.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Science and Technology Complex
- No. 7, Beinong Road, Science and Technology Park, Changping District
- Beijing, 102206
- China
+86 010 0000 0000
FutureGen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 01-Jan-2020 | $42.8M | 000.00 | Completed | Clinical Trials - General | |
| 3. Early Stage VC (Series A) | 16-Apr-2018 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC | 01-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
FutureGen Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Zhaoyu Jin Ph.D | FutureGen | Chairman Of the Board | 000 0000 |
FutureGen Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CICC Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| DYEE Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| MSA Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sinopharm Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lilly Asia Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |